Third, the optimal positioning and sequencing of GLP-1-based therapies relative to resmetirom and other emerging MASH agents (e.g., lanifibranor, pegozafermin, semaglutide combination regimens) requires dedicated combination trials, of which preliminary data from the MAESTRO-NASH secondary analysis are encouraging
doi: 10.1016/j.eplepsyres.2018.09.013 266 afakBAltunanBTopuBEren TopkayaA
Maintaining consistent treatment is crucial during this time, as the cumulative hormonal adjustments support normal follicular development
It is a widely used bioactive compound with substantial therapeutic and biological activity [155], including anti-inflammatory [246, 248], gut microbiota-regulating [139], anti-neuroinflammatory [141], and antioxidant effects[89], and is used to treat various diseases